ArticleBMC infectious diseases2022
Tuberculosis treatment adherence in the era of COVID-19.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of digital adherence technologies on treatment outcomes, adherence, and patient-reported outcomes in tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Effectiveness of a Mobile Health Intervention (DOT Selfie) in Increasing Treatment Adherence Monitoring and Support for Patients With Tuberculosis in Uganda: Randomized Controlled Trial.JMIR mHealth and uHealth · 2025Trial
- Design and Long-Term Sustainability of Mini Health Centers for Primary Healthcare in Chennai, India.Cureus · 2026Review
- The Feasibility of Implementing Interprofessional Collaboration-Based Telecare Services for Patients With Tuberculosis: A Mixed Methods Study From Hospital Insight.Interdisciplinary perspectives on infectious diseases · 2026Article
- Liver functions and medication adherence in tuberculosis patients after 6 months of antituberculosis treatment in Indonesia.The Journal of international medical research · 2025Article
- Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework.BMJ global health · 2025Article
- Contribution of Video Directly Observed Therapy (VDOT) to Tuberculosis Treatment in Brazil.Journal of medical systems · 2025Article
- Assessment of the impact of COVID-19 on tuberculosis care at a tertiary hospital: integrating lessons from COVID-19 learned.Frontiers in public health · 2025Article
- Effectiveness of Video-Observed Therapy in Tuberculosis Management: A Systematic Review.Cureus · 2024Review
- Telemedicine as a tool to prevent multi-drug resistant tuberculosis in poor resource settings: Lessons from Nigeria.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- The global impact of COVID-19 on tuberculosis: A thematic scoping review, 2020-2023.PLOS global public health · 2024Article
- Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.Dermatology and therapy · 2023Article
- Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies.Expert review of anti-infective therapy · 2023Review
- Electronic directly observed therapy (eDOT) therapy: a digital breakthrough in tuberculosis treatment - A commentary.Annals of medicine and surgery (2012) · 2023Article
- Trends in Tuberculosis Mortality Across India: Improvements Despite the COVID-19 Pandemic.Cureus · 2023Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
backgroundIn-person directly observed therapy (DOT) is commonly used for tuberculosis (TB) treatment monitoring in the US, with increasing usage of video-DOT (vDOT). We evaluated the impact of COVID-19 on TB treatment adherence, and utilization and effectiveness of vDOT.
methodsWe abstracted routinely collected data on individuals treated for TB disease in Baltimore, Maryland between April 2019 and April 2021. Our primary outcomes were to assess vDOT utilization and treatment adherence, defined as the proportion of prescribed doses (7 days/week) verified by observation (in-person versus video-DOT), comparing individuals in the pre-COVID and COVID (April 2020) periods.
resultsAmong 52 individuals with TB disease, 24 (46%) received treatment during the COVID-19 pandemic. vDOT utilization significantly increased in the COVID period (18/24[75%]) compared to pre-COVID (12/28[43%], p = 0.02). Overall, median verified adherence was similar pre-COVID and COVID periods (65% versus 68%, respectively, p = 0.96). Adherence was significantly higher overall when using vDOT (median 86% [IQR 70-98%]) compared to DOT (median 59% [IQR 55-64%], p < 0.01); this improved adherence with vDOT was evident in both the pre-COVID (median 98% vs. 58%, p < 0.01) and COVID period (median 80% vs. 62%, p = 0.01).
conclusionvDOT utilization increased during the COVID period and was more effective than in-person DOT at verifying ingestion of prescribed treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.